| Dr Jonathan W Hathaway, MD | |
|
601 28 1/4 Rd, Grand Junction, CO 81506-6022 | |
| (970) 263-2670 | |
| (970) 263-2686 |
| Full Name | Dr Jonathan W Hathaway |
|---|---|
| Gender | Male |
| Speciality | Pediatrics |
| Location | 601 28 1/4 Rd, Grand Junction, Colorado |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1023336906 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 208000000X | Pediatrics | 87985 (Georgia) | Primary |
| 208000000X | Pediatrics | 49992 (Tennessee) | Secondary |
| Entity Name | Privia Pediatric Medical Group Of Georgia Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1710385513 PECOS PAC ID: 3375861032 Enrollment ID: O20150409002405 |
News Archive
Human Genome Sciences, Inc. and GlaxoSmithKline PLC today announced topline secondary endpoints from BLISS-76, the second of two pivotal Phase 3 trials of BENLYSTA™ (belimumab) in seropositive patients with systemic lupus erythematosus.
About two years ago, Dr. Philippe Gros, a McGill University professor in the Department of Biochemistry and a Principal Investigator in thd McGill Life Sciences Complex, described a mouse mutant that was immunodeficient and hypersensitive to the Bacille Calmette-Gu-rin (BCG) vaccine and to tuberculosis (TB).
A new Harvard Medical School analysis shows that papers that present research on health conditions within sub-Saharan African countries in collaboration with wealthy or prestigious institutions or countries often fail to mention local researchers working on the same project, especially in prime positions such as first or senior author. The paper was published on October 18, 2019, in the journal BMJ Global Health.
La Jolla Pharmaceutical Company (Nasdaq: LJPC) announced today that it has received a notice from the Nasdaq Stock Market indicating that the Company is not in compliance with Nasdaq Marketplace Rule 5550(a)(2) (the "Minimum Bid Price Rule") because, for the last 30 consecutive days, the bid price for the Company's common stock has closed below the minimum level of $1.00 per share.
Commenting on the publication of the Health Committee report on its inquiry into the integration of health and social care, Dr Brian Keighley, chairman of the BMA in Scotland said:
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Jonathan W Hathaway, MD Po Box 1727, Grand Junction, CO 81502-1727 Ph: (970) 256-6322 | Dr Jonathan W Hathaway, MD 601 28 1/4 Rd, Grand Junction, CO 81506-6022 Ph: (970) 263-2670 |
News Archive
Human Genome Sciences, Inc. and GlaxoSmithKline PLC today announced topline secondary endpoints from BLISS-76, the second of two pivotal Phase 3 trials of BENLYSTA™ (belimumab) in seropositive patients with systemic lupus erythematosus.
About two years ago, Dr. Philippe Gros, a McGill University professor in the Department of Biochemistry and a Principal Investigator in thd McGill Life Sciences Complex, described a mouse mutant that was immunodeficient and hypersensitive to the Bacille Calmette-Gu-rin (BCG) vaccine and to tuberculosis (TB).
A new Harvard Medical School analysis shows that papers that present research on health conditions within sub-Saharan African countries in collaboration with wealthy or prestigious institutions or countries often fail to mention local researchers working on the same project, especially in prime positions such as first or senior author. The paper was published on October 18, 2019, in the journal BMJ Global Health.
La Jolla Pharmaceutical Company (Nasdaq: LJPC) announced today that it has received a notice from the Nasdaq Stock Market indicating that the Company is not in compliance with Nasdaq Marketplace Rule 5550(a)(2) (the "Minimum Bid Price Rule") because, for the last 30 consecutive days, the bid price for the Company's common stock has closed below the minimum level of $1.00 per share.
Commenting on the publication of the Health Committee report on its inquiry into the integration of health and social care, Dr Brian Keighley, chairman of the BMA in Scotland said:
› Verified 3 days ago
Dr. Tami Hutton Garmany, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 2635 N 7th St, Grand Junction, CO 81501 Phone: 970-244-2275 Fax: 970-244-2222 | |
Dr. Mary E Willy, DO Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 360 W Park Dr, Suite 201, Grand Junction, CO 81505 Phone: 970-609-7337 Fax: 970-233-9829 | |
David L. Pacini, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 1120 Wellington Ave, Grand Junction, CO 81501 Phone: 970-243-5437 Fax: 970-243-7792 | |
William A. Findlay, MD Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 3150 N 12th St, Grand Junction, CO 81506 Phone: 970-243-5437 Fax: 970-243-7792 | |
Jan Leah Lamb, D.O. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 603 28 1/4 Rd, Grand Junction, CO 81506 Phone: 970-263-2670 Fax: 970-263-2686 | |
Kate Sawicki, Pediatrics Medicare: Medicare Enrolled Practice Location: 360 W Park Dr Ste 201, Grand Junction, CO 81505 Phone: 970-609-7337 |